Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 5 from your keywords: subject="Vitor"
cover
Multicenter collaborative randomized parallel group comparative study of pita…
Comment Share
Yokote K

Japanese patients with total cholesterol (TC)≥220 mg/dL were randomized to receive pitavastatin 2mg (n = 126) or atorvastatin 10 mg (n = 125) for 12 weeks. The primary endpoint was percent change from baseline in non-HDL-C level after 12 weeks of treatment. Reduction of non-HDL-C by pitavastatin treatment (39.0%, P = 0.456 vs. atorvastatin) was non-inferior to that by atorvastatin (40.3%). B…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme …
Comment Share
Saito Y

Pitavastatin (CAS 147526-32-7, NK-104), the first totally synthetic 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor discovered in Japan, was examined. Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1 mg/day or more, and significant dose-dependence of the effect of this drug was ob…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Comparison of the Lipid-Lowering Effects of Pitavastatin 4mg Versus Pravastat…
Comment Share
Sponseller CA

Results froma Phase III, European, non-inferiority trial in elderly (age Z65 years) patients with primary hyperlipidemia or mixed(combined) dyslipidemia demonstrated significantly greater reductions in LDL-C for pitavastatin versus pravastatin across 3pair-wise dose comparisons (1mgvs10mg,2 mgvs20mg, and4mgvs40mg, respectively). The present study investigated whether pitavastatin 4mg is superi…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metabolic syndrome update
Comment Share
Grundy SM

The metabolicsyndromeisamultiplexriskfactorforatheroscleroticcardiovasculardiseaseandtype2diabetes.Itiscomposed of atherogenicdyslipidemia,elevatedbloodpressure,insulinresistanceandelevatedglucose,apro-thromboticstate,anda pro-inflammatorystate.Excessenergyintakeandconcomitantobesityarethemajordriversofthesyndrome.Lifestyle intervention canreversemetabolicriskfactors,butattimes,drugtherapies…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metabolic syndrome : Pathophysiology, Management, and Modulation by Natural C…
Comment Share
Yogita Rochlan

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribut…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-